Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was $0, compared with $21K a year earlier. Trailing-twelve-month research & development was $0. Over 3 fiscal years it compounded at -39.8% a year.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$21.37K— YoY
LTMMar 2026
$0-100.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR-39.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
21.37K USD
Year-over-year change
—
4-year CAGR
-29.8%

Research & Development vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +9.4%.
  • Research & development amounts to 0.0% of revenue for CPH.TO, versus a peer median of 1.5%.
CPH.TO Competitors
Research & Development for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$33.61M CAD+45.4%+25.2%6.6%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$4.85M CAD+31.9%-15.1%1.5%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$1.84M CAD-59.9%—66.7%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$205.18K USD-48.4%-58.4%0.4%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-39.8%0.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CPH.TO) —+9.4%-15.1%1.5%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.94M20.68M21.16M33.36M51.33M
Cost of Revenue3.68M3.99M4.07M9.26M17.56M
Gross Profit18.26M16.68M17.09M24.1M33.77M
Gross Margin83.2%80.7%80.8%72.2%65.8%
Research & Development88K98K139K021.37K
Selling, General & Admin5.11M4.4M5.43M12.24M16.3M
Operating Expenses6.45M5.63M5.56M16.26M16.97M
Depreciation & Amortization701K989K1.23M4.02M7.23M
EBITDA13.66M12.04M11.53M11.87M24.1M
EBITDA Margin62.2%58.2%54.5%35.6%46.9%
Operating Income11.82M12.04M11.53M7.85M16.8M
Operating Margin53.9%58.2%54.5%23.5%32.7%
Interest Income12K464K1.87M330K0
Interest Expense92K0001.19M
Other Income / Expenses(2M)(560K)1.15M(4.89M)661.38K
Income Before Tax11.06M11.48M12.68M2.96M17.46M
Pre-Tax Margin50.4%55.5%59.9%8.9%34.0%
Income Tax Expense3.3M(15.16M)(7.7M)(8.59M)(10.34M)
Net Income7.76M26.64M20.38M11.55M27.81M
Net Margin35.4%128.8%96.3%34.6%54.2%
EPS (Basic)0.291.060.800.471.09
EPS (Diluted)0.291.040.800.471.07
Weighted Avg Shares26.6M25.13M25.48M24.72M25.48M
Weighted Avg Shares (Diluted)26.83M25.59M25.42M24.57M25.99M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.